 |
|
Prototype test for predicting clinical outcome for melanoma patients
August 15, 2008Gene signature prognostication of rapid progression from Stage III to Stage IV
Investigators from the Melbourne Center of the international Ludwig Institute for Cancer Research (LICR) and Pacific Edge Biotchnology Ltd today reported that they have developed a test to predict whether a patient will progress rapidly from Stage III melanoma to metastatic Stage IV cancer and death.
More than 70% of patients with Stage III melanoma - melanoma that has spread to the lymph nodes - will typically have a rapid time to progression (TTP) to Stage IV melanoma, and pass away within five years of their diagnosis. However, the remaining <30% of patients will have a slow TTP to Stage IV and will have prolonged survival. Not being able to distinguish between these patient subtypes means that some patients might undergo aggressive, often toxic, treatments unnecessarily. The unpredictable and significant discrepancies in TTP and survival could also cloud the interpretation of results from clinical trials of new melanoma therapies.
The LICR Melbourne team, together with collaborators from Pacific Edge Biotechnology Limited in New Zealand, has developed a prototype test that can distinguish between these two patient subtypes with 85-90% accuracy. However, the team cautions that these findings must be validated in a larger number of patients before the test can be applied routinely as a prognostic tool.
According to the senior author of the study, LICR's Professor Jonathan Cebon, M.D., the predictive test could assist patients and their health care teams in making treatment decisions. Perhaps most importantly, being able to distinguish between the subtypes could have a tremendous impact on the development of new melanoma therapies. "One of the major problems we have in clinical trials for new melanoma therapies is that we can't identify the people who are going to have a slower disease progression no matter what they receive in a clinical trial," says Professor Cebon. "When new treatments are tested it is necessary to show clinical benefit by comparing patients who receive the new therapy with those who do not. Although patients might all have the same type of cancers, there can be big differences in their survival simply because their cancers behave differently - and this may have nothing to do with the treatment. If we are able to identify the good players and the bad players up-front, it becomes a whole lot easier figuring out whether good results are due to the new treatment or not. Most importantly far fewer patients would be needed for the clinical trials. It's partly because we can't clinically identify subtypes of patients that we have to do very large and very expensive trials. And, of course, this increases the time it takes to test the clinical benefit of potential new therapies."
The joint Australian/New Zealand team used microarrays to measure the expression of more than 30,000 genes in lymph node sections taken from 29 patients with Stage III melanoma. There were 2,140 genes differentially expressed in the sections from people who had already had a "poor" outcome (average TTP of just four months) and patients that had had a "good" outcome (average TTP of 40+ months). Using statistical analyses, the team identified 21 genes that could be used to differentiate between the two subtypes of patients in the retrospective analysis. This gene signature was then used to prospectively analyze another 10 patients, with the clinical outcome for nine of the 10 (90%) patients proving to be predicted accurately. The one patient who was incorrectly predicted to have a "good" prognosis did have a rapid TTP to Stage IV. However, this patient went on to have a prolonged survival of six years. The team also applied the test to published data sets and showed they could get a prediction accuracy of 85%, event though data was not available for all 21 genes in the published literature.
This study was conducted under the auspices of the Hilton - Ludwig Cancer Metastasis Initiative. It was led by investigators from: LICR Melbourne Center Austin Health, Melbourne, Australia; Department of Biochemistry, University of Otago, Otago, New Zealand; Pacific Edge Biotechnology Limited, Dunedin, New Zealand, and; Department of Statistics, University of Auckland, Auckland, New Zealand.
Ludwig Institute for Cancer Research
The LICR Melbourne team, together with collaborators from Pacific Edge Biotechnology Limited in New Zealand, has developed a prototype test that can distinguish between these two patient subtypes with 85-90% accuracy. However, the team cautions that these findings must be validated in a larger number of patients before the test can be applied routinely as a prognostic tool.
According to the senior author of the study, LICR's Professor Jonathan Cebon, M.D., the predictive test could assist patients and their health care teams in making treatment decisions. Perhaps most importantly, being able to distinguish between the subtypes could have a tremendous impact on the development of new melanoma therapies. "One of the major problems we have in clinical trials for new melanoma therapies is that we can't identify the people who are going to have a slower disease progression no matter what they receive in a clinical trial," says Professor Cebon. "When new treatments are tested it is necessary to show clinical benefit by comparing patients who receive the new therapy with those who do not. Although patients might all have the same type of cancers, there can be big differences in their survival simply because their cancers behave differently - and this may have nothing to do with the treatment. If we are able to identify the good players and the bad players up-front, it becomes a whole lot easier figuring out whether good results are due to the new treatment or not. Most importantly far fewer patients would be needed for the clinical trials. It's partly because we can't clinically identify subtypes of patients that we have to do very large and very expensive trials. And, of course, this increases the time it takes to test the clinical benefit of potential new therapies."
The joint Australian/New Zealand team used microarrays to measure the expression of more than 30,000 genes in lymph node sections taken from 29 patients with Stage III melanoma. There were 2,140 genes differentially expressed in the sections from people who had already had a "poor" outcome (average TTP of just four months) and patients that had had a "good" outcome (average TTP of 40+ months). Using statistical analyses, the team identified 21 genes that could be used to differentiate between the two subtypes of patients in the retrospective analysis. This gene signature was then used to prospectively analyze another 10 patients, with the clinical outcome for nine of the 10 (90%) patients proving to be predicted accurately. The one patient who was incorrectly predicted to have a "good" prognosis did have a rapid TTP to Stage IV. However, this patient went on to have a prolonged survival of six years. The team also applied the test to published data sets and showed they could get a prediction accuracy of 85%, event though data was not available for all 21 genes in the published literature.
This study was conducted under the auspices of the Hilton - Ludwig Cancer Metastasis Initiative. It was led by investigators from: LICR Melbourne Center Austin Health, Melbourne, Australia; Department of Biochemistry, University of Otago, Otago, New Zealand; Pacific Edge Biotechnology Limited, Dunedin, New Zealand, and; Department of Statistics, University of Auckland, Auckland, New Zealand.
Ludwig Institute for Cancer Research
Melanoma Current Events and Melanoma News RSSBenign or cancerous?
Research into a cancer that is on the rise in the UK is to be presented at the University of Leicester.
Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.
Substance tackles skin cancer from 2 sides
By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
MicroRNAs make for safer cancer treatments
Viruses -- long regarded solely as disease agents -- now are being used in therapies for cancer. Concerns over the safety of these so-called oncolytic viruses stem from their potential to damage healthy tissues.
Chronic inflammation can help nurture skin cancer, study shows
Inflammation, a frontline defense against infection or disease, can help nurture skin cancer, researchers have found.
Researchers Examine Evolution of Genes that Trigger the Body's Immune Response to Viral Infection
Virginia Commonwealth University Institute of Molecular Medicine researchers have traced the evolutionary origin of two genes that serve as primary cellular sensors of infection with RNA viruses, such as influenza, poliovirus, West Nile virus, and HIV, which may ultimately provide researchers with insight into a possible new pathway for the development of innate immunity.
Scripps research scientists enhance immune system attacks on cancer
In an Early Edition issue of the Proceedings of the National Academy of Sciences (PNAS) published online on October 20, 2008, the scientists describe how they used multiple tactics to rev up both innate and adaptive immunity to enhance the body's ability to fight cancer.
Children's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
More Melanoma Current Events and Melanoma News Articles
 | The Melanoma Book: A Complete Guide to Prevention and Treatment, Including the Early DetectionSelf-Exam Body Map by Howard L. Kaufman From the founder and Co-Director of the renowned Columbia University Melanoma Center, the first comprehensive guide to help you prevent—and survive—a diagnosis of melanoma. The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a... |
 | Pathology of Malignant Melanoma by Raymond L. Barnhill An excerpt from "Pathology of Melanocytic Nevi and Malignant Melanoma, Second Edition", Pathology of Malignant Melanoma provides a highly practical approach to the histopathological diagnosis of melanoma of the skin. Emphasis is placed on the differential diagnosis of major forms of conventional melanoma, and the book also discusses unusual or rare variants that are difficult to recognize. This... |
 | The Definitive Guide to Melanoma by Lowndes Harrison The reassuring tone and clear explanations in this medical handbook provide valuable information to patients and family members struggling to understand a diagnosis of melanoma. Each year, more than 50,000 people in the U.S. learn that they have melanoma, and many of them are either young or elderly. This guide fills the information gap that develops between the initial diagnosis in the doctor's... |
 | 100 Questions & Answers about Melanoma & Other Skin Cancers by Edward F. McClay, Mary-Eileen T. McClay, Jodie Smith This book deals with skin cancer from a doctor's and a patient's... |
 | Pathology of Melanocytic Nevi and Malignant Melanoma Highly acclaimed and considered the leading reference in the field, Pathology of Melanocytic Nevi and Malignant Melanoma has now been fully revised and updated to accomodate rapid advances in the field of melanoma pathology. Drs. Michael Piepkorn and Klaus Busam have now joined Dr. Barnhill, world-renowned expert in dermatology and pathology, to expand the text with new sections on the genetics... |
 | Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness) by Catherine M. Poole, IV DuPont Guerry The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early... |
 | What You Really Need to Know about Moles and Melanoma (A Johns Hopkins Press Health Book) by Jill R. Schofield, William A. Robinson Throughout the world, the incidence of malignant melanoma is increasing at an alarming rate. This dramatic rise is largely due to more frequent and prolonged exposure to intense sun, the result of major changes in clothing styles, recreation, and lifestyle (including widespread access to midwinter resort vacations). Significantly, recent scientific studies have shown an increased number of moles... |
 | Understanding Melanoma: What You Need to Know by Perry Robins; MD and Maritza Perez; MD Newly updated and now in its third edition, this handbook is written for melanoma patients, their families and friends, health professionals, and every person with an interest in the disease. This valuable book, written by two eminent dermatologist, tells all about melanoma from the moment of diagnosis through state- of-the-art treatments. Honest and straightforward, but reassuring in tone.... |
 | Sun and the Epidemic of Melanoma: Myth on Myth by Bernard A. Ackerman This work concerns the sun and the epidemic of melanoma. This endeavor aims, at a minimum, to examine claims made about the effects of the sun not only on the development of primary cutaneous melanoma, but on an efflorescence of melanomas. But our purpose transcends those matters, being directed as it is to diverse issues in many disciplines of medicine that are mired today in fallacy, fad, and... |
 | Sentinel Lymph Node Biopsy Has No Benefit for Patients with Primary Cutaneous Melanoma: An Assertion Based on Comprehensive, Critical Analysis by Neil Medalie, A. Bernard Ackerman |
| © 2008 BrightSurf.com |